STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others…
ImpactNotable
Published5 h ago (Mon, 16 Nov 2026 18:18:25 GMT)
AuthorEd Silverman
MoreLess
Impact score33/100
RatingProbability of 68%.
RegionsGlobal
Retrievedvia rss
ClassifiedMon, 16 Nov 2026 19:01:24 GMT by classifier